<DOC>
	<DOCNO>NCT02724527</DOCNO>
	<brief_summary>Cavosonstat ( N91115 ) study potential novel therapy cystic fibrosis ( CF ) , study ass target population patient heterozygous F508del-CFTR gating mutation approve treatment ivacaftor ( G551D , G1244E , G1349D , G178R , G551S , S1251N , S1255P , S549N , S549R ) .</brief_summary>
	<brief_title>Study Cavosonstat ( N91115 ) CF Patients Who Are Heterozygous F508del-CFTR Gating Mutation Being Treated With Ivacaftor</brief_title>
	<detailed_description>Assess effect Cavosonstat ( N91115 ) lung function add preexist treatment ivacaftor adult patient CF heterozygous F508del-CFTR gating mutation approve treatment ivacaftor ( G551D , G1244E , G1349D , G178R , G551S , S1251N , S1255P , S549N , S549R ) .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Confirmed diagnosis CF , heterozygous F508delCFTR gate mutation approve treatment ivacaftor ( G551D , G1244E , G1349D , G178R , G551S , S1251N , S1255P , S549N , S549R ) Have treat chronic ivacaftor twice daily least 6 month prior Screening ( date consent ) currently treat commercially available Ivacaftor Negative serum pregnancy test Weight ≥ 40 kg screen Oxygen saturation pulse oximetry ≥ 90 % breathe ambient air , screen Any acute infection , include acute upper low respiratory infection pulmonary exacerbation require treatment complete within 2 week Study Day 1 hospitalization discharge within 2 week Study Day 1 Recent infection ( per investigator discretion ) organisms associate rapid decline pulmonary status , example : Burkholderia cenocepacia , Burkholderia dolosa , Mycobacterium abscessus Any change regimen chronic therapy CF lung disease ( e.g. , Pulmozyme® , hypertonic saline , Azithromycin , TOBI® , Cayston® ) within 4 week Study Day 1 Blood hemoglobin &lt; 10 g/dL screen Serum albumin &lt; 2.5 g/dL screen Abnormal liver renal function History ventricular tachycardia clinically significant ventricular arrhythmia History , include screen assessment , prolong QT and/or QTcF ( Fridericia 's correction ) interval ( &gt; 450 msec men ; &gt; 470 msec woman ) History solid organ hematological transplantation History alcohol abuse drug abuse ( include cannabis , cocaine , opioids ) year prior screen Use continuous ( 24 hr/day ) nocturnal supplemental oxygen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>N91115</keyword>
	<keyword>Cavosonstat</keyword>
</DOC>